Abstract:Background: Ondansetron oral soluble film is designed to be applied on top of the tongue without requiring water to aid dissolution or swallowing, which is especially fitting for nausea and vomiting patients. Purpose: This study was conducted to compare the bioavailability of two 8 mg ondansetron oral soluble film formulations. Patients and methods: This randomized, open-label, two-period crossover study was performed under fasting conditions. A total of ten eligible subjects were randomly assigned at a 1: 1 ratio to receive a single 8 mg dose of the test and reference ondansetron oral soluble film formulations, followed by a 1-week washout period and administration of the alternate formulation. The concentrations of ondansetron were assayed using an liquid chromatographmass spectrometer/mass spectrometer (LC-MS/MS) method. For analysis of pharmacokinetic properties, including the peak concentration of T-max (C-max), AUC from time 0 (baseline) to t hours (AUC(0-t)), and AUC from baseline to infinity (AUC(0-infinity)), blood samples were obtained at intervals over the 24-hour period after studying drug administration. Tolerability was assessed by monitoring vital signs and laboratory tests (hematology, blood biochemistry, hepatic function, and urinalysis) and by questioning subjects about adverse events. Results: The mean (standard derivation [SD]) relative bioavailability was 96.5 (23.7%). The 90% confidence intervals (CIs) for the log-transformed ratios of C-max and AUC(0-t) were 84.71%-103.28% and 91.38%-108.60%, respectively (P>0.05). Similar results were found for the data without log-transformation. No statistically significant differences were found based on analysis of variance. No significant adverse events occurred or were reported during the study. Conclusion: As the 90% CIs based on the differences between the test and reference formulation were within the 80%-125% range for both the C-max and AUC(0-t), we concluded that the two formulations were bioequivalent with respect to the rate or the extent of absorption. Both formulations are well tolerated.

Bioequivalance of tropisetron granule in healthy volunteers after a single oral administration

Studies on the Bioequivalence of Lorazepam Tablet in Healthy Volunteers

Study on bioequivalence of cilostazol table in healthy volunteers

Studies on Bioequivalence of Ramipril Capsule in Healthy Volunteers

[Pharmacokinetics and Relative Bioavailability of Ziprasidone Tablets in Chinese Healthy Volunteers].

Bioavailability and Bioequivalence of Ondansetron Orally Disintegrating Tablets and Conventional Tablets

Bioequivalent Study of Citalopram Tablets

Pharmacokinetics and bioequivalence of topiramate tablets in healthy volunteers

Evaluation of the Bioequivalence and Pharmacokinetics of Two Formulations of Rizatriptan after Single Oral Administration in Healthy Volunteers

Study on Bioequivalence of Risperidone Tablets

Bioequivalence study of fluoxetine capsules in healthy volunteers

Pharmacokinetics and Bioequivalance of Ambroxol Dispersible Tablets in Healthy Volunteers

Bioequivalence of Lansoprazole Enteric Caspsules in Healthy Volunteers

Pharmacokinetics and bioavailability study of two ondansetron oral soluble film formulations in fasting healthy male Chinese volunteers

Evaluation of Bioequivalence of Mirtazapine Tablets

Bioequivalence Evaluation of Two Rabeprazole Enteric Coated Formulations in Healthy Chinese Volunteers

Pharmacokinetics and bioequivalence evaluation of two oral formulations of cotrimoxazole tablets in healthy Chinese volunteers under fasting conditions

Pharmacokinetics of single oral dose trazodone: a randomized, two-period, cross-over trial in healthy, adult, human volunteers under fed condition

Bioequivalence of Glipizide Controlled-Release Tablets in Chinese Healthy Volunteers

Bioeguivalent Study of Two Fluconazole Capsules in Human Plasma

Relative bioavailability of cefpodoxime proxetil tablets in healthy volunteers